Thank you! Katy Rezvani, M.D., Ph.D Honored to share our work on engineered NK cells and the promise of cord blood therapies at #ASTCT. Grateful to be part of such an innovative and collaborative field! #NKCells #CellTherapy MD Anderson Cancer Center

It was a superb Greater Houston Partnership Board Meeting today as MD Anderson Cancer Center' Dr. Katy Rezvani shared the groundbreaking work underway within the Institute for Cell Therapy Discovery & Innovation. This area of science continues to develop in tremendous ways for the benefit of patients

Thank you Dr. Pisters - it was an honor to share the progress being made at the Institute for Cell Therapy Discovery & Innovation! Very grateful to Greater Houston Partnership for the opportunity to showcase our efforts to bring transformative cell therapies to patients. Looking forward to

So fun to meet with all these breast cancer experts and talk about stromal barriers to cell therapies along with the brilliant Hind Rafei and Hila Shaim at the ABC breast cancer conference. Power team representing from Katy Rezvani, M.D., Ph.D MD Anderson Cancer Center !! Pavlos Msaouel Isaac Chan, MD, PhD

A pleasure to learn from Global Cell Therapy Leader Dr. Katy Rezvani of MD Anderson Cancer Center! She delivered a phenomenal Grand Rounds on the promise and clinical efficacy of NK CAR therapy. The future of cell therapy is truly exciting! 🔬✨ #CARNK #CellTherapy

I am looking for a postdoc interested in modeling cells and other biological entities/phenomena using AI, physical modeling, and other approaches. jobs.mdanderson.org/Search/JobDeta…

The trailblazing CAR-NK pioneer Katy Rezvani, M.D., Ph.D nk2025.au Discover Tasmania SNI NK Meeting

Congratulations to Katy Rezvani, M.D., Ph.D,Dr. @YagoNieto & team! Proud to be part of our Nature Medicine study:AFM13-NK cells in r/r CD30+ lymphomas with incredible results—92.9% ORR, 66.7% CR. First clinical proof of NK redirection!Excited for next-gen NK+engagers! #NKcells #Immunotherapy

Allogeneic NK cells precomplexed with a bispecific (CD30/CD16) NK cell engager (AFM13) in refractory relapsed lymphoma: a phase 1 trial. N=42, ORR: 92%, 2-year EFS: 26% #bmtsm #lymsm MD Anderson Cancer Center Katy Rezvani, M.D., Ph.D Rafet Nature Medicine nature.com/articles/s4159…

On this episode of the Cancerwise podcast, Drs. Scott Kopetz and Katy Rezvani break down cell therapy and the different ways to engineer cells for certain disease types. They discuss the advancements that may help patients get treatment sooner: brnw.ch/21wRWpg #EndCancer

“Incredibly proud of my lifelong friend May Daher and our brilliant collaborator @collasimona for this fantastic paper on my latest favorite topic: MDS/AML. Huge congratulations — and here’s to many more! MD Anderson Cancer Center

Brilliant work! congratulations, May Daher and simona colla and co-authors. Fascinating insight into how early NK cell dysfunction contributes to immune escape in MDS, and a compelling case for the therapeutic potential of adoptive NK cell transfer. Looking forward to seeing

Huge congratulations to Anirban Maitra Linghua Wang, MD, PhD,and the entire team at MD Anderson Cancer Center and collaborators! Incredible work on advancing our understanding of metastatic #PancreaticCancer—this spatial transcriptomic mapping study in nature is a major achievement!

This morning at #AACR25, our Dr. Katy Rezvani shared an overview of her team’s wide-ranging CAR NK cell platform targeting hematological malignancies and solid tumors, leading to 12 ongoing clinical trials. Katy Rezvani, M.D., Ph.D AACR #EndCancer

Congratulations to Alexander Biederstädt, MD on an outstanding presentation #AACR25, showcasing a novel platform for genome-wide CRISPR screening in primary human CAR NK cells. So proud of your achievements and excited to watch your continued impact in the field. #NKcells MD Anderson Cancer Center

Headed back to HTX from Chicago and this is what I saw at O'Hare Intl. Airport. The most powerful brand in cancer care - the global leader:

At #ASCO25, Dr. Katy Rezvani reviewed recent natural killer (NK) cell trials showing these cells can still be detected in patients more than a year later. The potential? An off-the-shelf cell therapy that could expand access and reduce costs for patients in need. #EndCancer

Excited to share our Cancer Cell Cell Press article on the discovery of the IL-15 Receptor "Regulome". A technical tour-de-force from the Immunology, computational biology & functional genomics teams oNKo-innate Monash Biomedicine Discovery Institute

Congrats to Nicholas Huntington and team on their Cancer Cell paper! CRISPR screens identify UBE2F and ARIH2 as key brakes on IL-15R signaling in NK cells. Targeting them improves NK & CAR-NK anti-tumor activity, uncovering promising targets for immunotherapy. #NKcells #CAR_NK #IL15

Harnessing engineered NK cells for refractory CD30+ lymphoma dlvr.it/TLXJ2y #genetherapy #celltherapy